Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Li N, Zheng SR, Zhang SW, et al. Analysis and prediction of breast cancer incidence trend in China. Chin J Preventive Med. 2012;46(8):703–707.
   Google Scholar
• Waks AG, Winer EP. Breast cancer treatment. JAMA. 2019;321(3):288. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35(27):3105–3112. doi:10.1200/JCO.2016.69.6179
   PubMed Web of Science ®Google Scholar
• Li Q, Guan X, Chen S, et al. Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2 positive metastatic breast cancer patients: a phase I clinical trial. Clin Cancer Res. 2019;25(17):5212–5220. doi:10.1158/1078-0432.CCR-18-4173
   PubMed Web of Science ®Google Scholar
• Ma F, Ouyan Q, LI W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized phase II Study. J Clin Oncol. 2019;37(29):2610–2619. doi:10.1200/JCO.19.00108
   PubMed Web of Science ®Google Scholar
• Yan M, Bian L, Hu X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized double-blind placebo-controlled Phase 3 study. Transl Breast Cancer Res. 2020;1:13. doi:10.21037/tbcr-20-25
   Google Scholar
• Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicenter, open-label, randomized, controlled phase 3 trial. Lancet Oncol. 2021;22(3):351–360. doi:10.1016/S1470-2045(20)30702-6
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Soto-Perez-de-Celis E, Li D, Yuan Y, et al. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19(6):e305–e316. doi:10.1016/S1470-2045(18)30348-6
   PubMed Web of Science ®Google Scholar
• Won HS, Lee KE, Sung SH, et al. Topoisomerase II alpha and microtubule associated protein-tau as a predictive marker in axillary lymph node positive breast cancer. Tumori. 2014;100(1):80–86. doi:10.1177/1430.15820
   PubMed Web of Science ®Google Scholar
• Blair HA. Pyrotinib: first global approval. Drugs. 2018;78(16):1751–1755. doi:10.1007/s40265-018-0997-0
   PubMed Web of Science ®Google Scholar
• Jun-cheng Xuhong XQ. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res. 2019;9(10):2103–2119.
   PubMed Web of Science ®Google Scholar
• Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist. 2007;12(7):766–773. doi:10.1634/theoncologist.12-7-766
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2 positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–4843. doi:10.1158/1078-0432.CCR-10-2962
   PubMed Web of Science ®Google Scholar
• Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013;22(4):525–531. doi:10.1016/j.breast.2012.12.006
   PubMed Web of Science ®Google Scholar
• Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(27):2804–2807. doi:10.1200/JCO.2018.79.2713
   PubMed Web of Science ®Google Scholar
• Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–1649. doi:10.1016/j.annonc.2020.09.010
   PubMed Web of Science ®Google Scholar
• Tanguturi S, Warren L. The current and evolving role of radiation therapy for central nervous system metastases from breast cancer. Curr Oncol Rep. 2019;21(6):50. doi:10.1007/s11912-019-0803-5
   PubMed Web of Science ®Google Scholar
• Brosnan EM, Anders CK. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med. 2018;6(9):163. doi:10.21037/atm.2018.04.35
   PubMed Web of Science ®Google Scholar
• Sullivan O, Davarpanah NN, Abraham J, et al. Current challenges in the management of breast cancer brain metastases. Semin Oncol. 2017;44(2):85–100. doi:10.1053/j.seminoncol.2017.06.006
   PubMed Web of Science ®Google Scholar
• Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers. 2021;13(12):2927. doi:10.3390/cancers13122927
   PubMed Web of Science ®Google Scholar
• Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, Phase 2 trial. Lancet Oncol. 2022;23(3):353–361. doi:10.1016/S1470-2045(21)00716-6
   PubMed Web of Science ®Google Scholar